New Haven, CT Clinical Trials Report — July 2026

People in New Haven who may qualify for a clinical trial should act now if their condition matches a study nearing its enrollment deadline. 30 recruiting trials are expected to close within the next 90 days, including 5 that accept healthy volunteers. New Haven currently has 823 recruiting trials across 257 research facilities, so participants have a broad local selection—but individual studies may stop enrolling before their projected closing date.

Closing-soon opportunities for patients and healthy volunteers

The closing pipeline includes studies involving alcohol use and alcohol-related disorders, advanced cancers, acute myeloid leukemia, atrial fibrillation, and atopic dermatitis. Alcohol-related research is especially visible among the near-term deadlines, while oncology studies include advanced malignant neoplasms, advanced solid tumors, and AML with mutated NPM1.

• Alcohol use and alcohol-related disorders (5 trials across the listed alcohol categories)
• Advanced malignant neoplasm (1 trial)
• Advanced solid tumor (1 trial)
• Acute myeloid leukemia, including AML with mutated NPM1 (2 trials across the listed AML categories)
• Atrial fibrillation (1 trial)
• Atopic dermatitis (1 trial)

Healthy volunteers should move quickly because 5 closing-soon studies accept healthy participants, compared with 96 healthy-volunteer trials recruiting across New Haven overall. Eligibility can depend on age, medications, health history, laboratory results, and the time required for visits, so contacting the study team early is the best way to determine whether a slot remains.

New Phase 2 and Phase 3 studies at Yale and local sites

New Haven opened 9 trials in July, up from 6 in June and below the earlier 2026 totals of 20 in February, 14 in March, 17 in April, and 14 in May. Drug studies account for 7 of the new openings, with one behavioral study and one study classified as other. The new-trial mix spans cancer, diabetes, epilepsy, alcohol use disorder, grief, loneliness, and healthy adults.

• NCT07700979 is Akeso’s Phase 3 study of cadonilimab combined with chemotherapy, compared with chemotherapy with or without nivolumab, for previously untreated, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. The planned enrollment is 900 participants.
• NCT07702578 is a Phase 3 TScan Therapeutics study evaluating genetically randomized, T-cell receptor-engineered donor T cells after allogeneic peripheral blood stem cell transplantation. The study plans to enroll 310 participants.
• NCT07723963 is Jazz Pharmaceuticals’ Phase 2/Phase 3 study of JZP926 capsules for juvenile myoclonic epilepsy, with planned enrollment of 260 participants.
• NCT07730294 is a Yale University Phase 2 study testing intranasal oxytocin, TNX-1900, for pain relief and recovery after pituitary surgery. It expects 75 participants.
• NCT07689877, the Yale University GUIDE Study, examines whether integrated digital health support—with and without healthcare-provider engagement—can improve glycemic control and diabetes-related outcomes in adults with type 2 diabetes. Planned enrollment is 300 participants.
• NCT07689864, the Yale-wide UNIFY liquid biopsy master repository, will prospectively collect blood samples, dried blood spots, and optional archival tissue from Yale Cancer Center patients across tumor types for current and future research. It plans to include 2,500 participants.

Yale University sponsors 5 of July’s new studies. Industry sponsors account for 4, including Akeso, Jazz Pharmaceuticals, Pfizer, and TScan Therapeutics. The sponsor mix is otherwise classified as 5 academic or other studies and 4 industry studies. Pfizer has one new opening in the city, although the supplied data does not identify its specific study.

Where New Haven has the deepest access

Yale-affiliated institutions dominate New Haven’s research landscape, giving residents access to oncology, transplantation, diabetes, neurology, behavioral health, and other specialties. Yale University leads with 248 recruiting trials, far ahead of other individual facilities in the city.

• Yale University (248 trials)
• Yale Cancer Center (71 trials)
• Yale New Haven Hospital (56 trials)
• Yale University School of Medicine (55 trials)
• Yale School of Medicine (36 trials)
• Smilow Cancer Center/Yale-New Haven Hospital (24 trials)
• Research Site (17 trials)
• Yale-New Haven Hospital (13 trials)
• Yale (10 trials)
• Connecticut Mental Health Center (9 trials)
• Smilow Cancer Hospital at Yale New Haven (8 trials)
• GSK Investigational Site (8 trials)

For people seeking cancer studies, Yale Cancer Center and the Smilow Cancer Center/Yale-New Haven Hospital sites are particularly prominent. Yale University, Yale School of Medicine, and Yale New Haven Hospital also provide broad access to metabolic, neurologic, behavioral, and hospital-based research.

Healthy volunteers and eligibility in July

Two of July’s 9 new trials accept healthy volunteers, including a study category specifically involving healthy adults. One new study includes children, while 8 include older adults. No new trial is limited to female participants or male participants. These figures describe July’s new openings; the broader citywide pool includes 96 recruiting trials that accept healthy volunteers.

People with alcohol-related conditions, AML, advanced cancer, atopic dermatitis, atrial fibrillation, diabetes, juvenile myoclonic epilepsy, or gastric and gastroesophageal junction cancer should review the closing-soon list first. Healthy adults should also contact study teams promptly, particularly for trials with limited screening windows.

Other Connecticut cities to consider

Participants willing to travel can also search nearby Connecticut locations. Recruiting trials are listed in Farmington, Hartford, Milford, North Haven, Waterbury, and West Haven, with 1 trial reported in each city. These options may be useful when a New Haven study has restrictive eligibility, a full screening schedule, or a specialty not available at the preferred Yale-affiliated site.

With July openings rising from June and a substantial number of studies approaching their expected deadlines, New Haven participants can expect continued movement in the local research calendar. Checking eligibility now—and asking whether a study is still screening—will provide the best chance of accessing both new late-stage drug trials and healthy-volunteer opportunities as August develops.